BRIGHTGENE Trademark

Trademark Overview


On Monday, October 28, 2019, a trademark application was filed for BRIGHTGENE with the United States Patent and Trademark Office. The USPTO has given the BRIGHTGENE trademark a serial number of 79278137. The federal status of this trademark filing is REGISTERED as of Tuesday, August 31, 2021. This trademark is owned by BrightGene Bio-Medical Technology Co., Ltd.. The BRIGHTGENE trademark is filed in the Pharmaceutical Products category with the following description:

Injectable solutions for medical purposes for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; prepared Chinese medicine for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; chemical pharmaceutical preparations for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; medicinal preparations for the mouth in the form of tablets or compressed tablets for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; medicines for human purposes for treatment of cardiovascular dise...
brightgene

General Information


Serial Number79278137
Word MarkBRIGHTGENE
Filing DateMonday, October 28, 2019
Status700 - REGISTERED
Status DateTuesday, August 31, 2021
Registration Number6465606
Registration DateTuesday, August 31, 2021
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 15, 2021

Trademark Statements


Goods and ServicesInjectable solutions for medical purposes for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; prepared Chinese medicine for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; chemical pharmaceutical preparations for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; medicinal preparations for the mouth in the form of tablets or compressed tablets for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; medicines for human purposes for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; biochemical medical drug for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; pharmaceutical preparations for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; chemical preparations for medical purposes for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; drugs for medical purposes for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders; active pharmaceutical ingredients for treatment of cardiovascular diseases, cerebrovascular diseases, viral infection, tumors, fungal infections, bacterial infection, iron-deficiency disease, and immune system disorders
Pseudo MarkBRIGHT GENE

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, February 10, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBrightGene Bio-Medical Technology Co., Ltd.
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressCN

Party NameBrightGene Bio-Medical Technology Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressCN

Party NameBrightGene Bio-Medical Technology Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressCN

Trademark Events


Event DateEvent Description
Sunday, February 27, 2022FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, February 7, 2022FINAL DISPOSITION NOTICE SENT TO IB
Monday, February 7, 2022FINAL DISPOSITION PROCESSED
Tuesday, November 30, 2021FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, August 31, 2021REGISTERED-PRINCIPAL REGISTER
Saturday, July 24, 2021NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Wednesday, July 7, 2021NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, July 7, 2021NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Tuesday, June 15, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 15, 2021PUBLISHED FOR OPPOSITION
Sunday, June 13, 2021NOTIFICATION PROCESSED BY IB
Wednesday, May 26, 2021NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, May 26, 2021NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, May 26, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, May 10, 2021ASSIGNED TO LIE
Monday, May 10, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, October 20, 2020NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, October 20, 2020LETTER OF SUSPENSION E-MAILED
Tuesday, October 20, 2020SUSPENSION LETTER WRITTEN
Friday, September 18, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, September 17, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, September 17, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, September 17, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, September 17, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, September 17, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, September 17, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, September 17, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, April 17, 2020REFUSAL PROCESSED BY IB
Friday, March 27, 2020NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, March 26, 2020REFUSAL PROCESSED BY MPU
Thursday, March 12, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, March 11, 2020NON-FINAL ACTION WRITTEN
Tuesday, March 10, 2020NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Wednesday, February 19, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, February 18, 2020NON-FINAL ACTION WRITTEN
Friday, February 14, 2020APPLICATION FILING RECEIPT MAILED
Monday, February 10, 2020ASSIGNED TO EXAMINER
Monday, February 10, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, February 6, 2020SN ASSIGNED FOR SECT 66A APPL FROM IB